【 文献重点摘要 】

Background

Laser therapy in patients with skin of color is associated with an increased rate of complications. The 755-nm picosecond laser with the diffractive lens array (DLA) has been used for the treatment of scars, striae, and rejuvenation. By delivering high energy to focused areas, the DLA minimizes complications.

Objective

This study explores the adverse events associated with treatment with the 755-nm picosecond laser with DLA in individuals with Fitzpatrick skin type IV to VI.

Method

A retrospective chart review of patients treated with the 755-nm picosecond laser with DLA with a standardized spot size of 6 mm, fluence of 0.71 J/cm2, and pulse width of 750 to 850 picoseconds was performed. Standard clinical photographs were obtained before treatment and at follow-up. Treatment sites were assessed for dyspigmentation, erythema, edema, and herpetic lesions.

Results

A total of 56 patients with Fitzpatrick skin type IV to VI, atrophic and hypertrophic scars, and pigmented lesions or striae were included. Ten patients (17.9%) were lost to follow-up. Transient adverse events, most commonly erythema and hyperpigmentation, were reported after therapy; these resolved in all cases.

Limitations

Retrospective design is a limitation.

背景

有色皮肤患者接受激光治疗会增加并发症的发生率。带有衍射透镜阵列(DLA)的755 nm皮秒激光已用于治疗瘢痕、条纹和嫩肤。通过向聚焦区域提供高能量，DLA将并发症降至最低。

目的

探讨755 nm皮秒激光联合DLA治疗Ⅳ~VI型Fitzpatrick皮肤的不良反应。

方法

对755 nm皮秒激光联合DLA治疗的患者进行回顾性分析，标准光斑尺寸为6 mm，光通量为0.71J/cm2，脉冲宽度为750~850皮秒。治疗前和随访时均获得标准的临床照片。评估治疗部位是否有色素不良、红斑、水肿和疱疹皮损。

结果

共纳入56例Fitzpatrick皮肤IV~VI型、萎缩性和增生性瘢痕、色素性病变或条纹患者。失访10例(17.9%)。治疗后报告了短暂的不良事件，最常见的是红斑和色素沉着；这些在所有病例中都得到了解决。

限制

回顾性设计是一个限制。